3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Sell
43
SWTX Quote, Financials, Valuation and Earnings
Last price:
$49.75
Seasonality move
:
-16.77%
Day range:
$50.31 - $52.40
52-week range:
$28.21 - $62.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.69x
P/B ratio:
7.93x
Volume:
1.6M
Avg. volume:
3.2M
1-year change:
2.27%
Market cap:
$3.8B
Revenue:
$191.6M
EPS (TTM):
-$3.48
Analysts' Opinion
-
Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $72.88, SpringWorks Therapeutics has an estimated upside of 43.23% from its current price of $50.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $63.00 representing 100% downside risk from its current price of $50.88.
Fair Value
-
According to the consensus of 5 analysts, SpringWorks Therapeutics has 43.23% upside to fair value with a price target of $72.88 per share.
SWTX vs. S&P 500
-
Over the past 5 trading days, SpringWorks Therapeutics has overperformed the S&P 500 by 3.64% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
SpringWorks Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
SpringWorks Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter SpringWorks Therapeutics reported revenues of $61.5M.
Earnings Growth
-
SpringWorks Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter SpringWorks Therapeutics reported earnings per share of -$1.04.
Enterprise value:
3.5B
EV / Invested capital:
7.28x
Price / LTM sales:
19.69x
EV / EBIT:
--
EV / Revenue:
18.29x
PEG ratio (5yr expected):
-23.33x
EV / Free cash flow:
-17.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$179M
Return On Assets:
-40.38%
Net Income Margin (TTM):
-134.73%
Return On Equity:
-46.69%
Return On Invested Capital:
-46.69%
Operating Margin:
-132.16%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $191.6M | $5.4M | $61.5M | |
| Gross Profit | -- | $5M | $179M | $5M | $56M | |
| Operating Income | -$280.7M | -$343M | -$278.1M | -$98.5M | -$81.3M | |
| EBITDA | -$279.9M | -$341.3M | -$274.7M | -$97.9M | -$80.3M | |
| Diluted EPS | -$5.21 | -$5.15 | -$3.48 | -$1.45 | -$1.04 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $513.4M | $382.9M | $599.8M | $500.9M | $380.5M | |
| Total Assets | $576.2M | $452.5M | $630.2M | $725.8M | $587.3M | |
| Current Liabilities | $17.6M | $30M | $51M | $78.2M | $100M | |
| Total Liabilities | $19.1M | $30.1M | $72.1M | $99.6M | $106.2M | |
| Total Equity | $557.1M | $422.4M | $558.2M | $626.2M | $481.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$161.6M | -$222.8M | -$175.6M | -$62.7M | -$29.5M | |
| Cash From Investing | -$215.6M | $34.8M | $64.5M | -$159.2M | $14.1M | |
| Cash From Financing | $340.7M | $296.6M | $4.8M | $299.1M | $653K | |
| Free Cash Flow | -$171.8M | -$230.2M | -$196.3M | -$60.4M | -$35.6M | |
SWTX
Sector
Market Cap
$3.8B
$38.4M
Price % of 52-Week High
82.07%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
0.31%
-0.78%
1-Year Price Total Return
2.27%
-39.05%
Beta (5-Year)
0.757
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$51.96
200-day SMA
Buy
Level
$38.63
Bollinger Bands (100)
Buy
Level
31.42 - 48.06
Chaikin Money Flow
Sell
Level
-5.5M
20-day SMA
Sell
Level
$54.59
Relative Strength Index (RSI14)
Buy
Level
51.64
ADX Line
Buy
Level
36.17
Williams %R
Neutral
Level
-68.6809
50-day SMA
Buy
Level
$44.14
MACD (12, 26)
Buy
Level
1.84
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
25.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.779)
Sell
CA Score
(Annual)
Level (-0.6846)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.7507)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
Stock Forecast FAQ
In the current month, SWTX has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SWTX average analyst price target in the past 3 months is $72.88.
-
Where Will SpringWorks Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that SpringWorks Therapeutics share price will rise to $72.88 per share over the next 12 months.
-
What Do Analysts Say About SpringWorks Therapeutics?
Analysts are divided on their view about SpringWorks Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SpringWorks Therapeutics is a Sell and believe this share price will drop from its current level to $63.00.
-
What Is SpringWorks Therapeutics's Price Target?
The price target for SpringWorks Therapeutics over the next 1-year time period is forecast to be $72.88 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SWTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for SpringWorks Therapeutics is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SWTX?
You can purchase shares of SpringWorks Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SpringWorks Therapeutics shares.
-
What Is The SpringWorks Therapeutics Share Price Today?
SpringWorks Therapeutics was last trading at $49.75 per share. This represents the most recent stock quote for SpringWorks Therapeutics. Yesterday, SpringWorks Therapeutics closed at $50.88 per share.
-
How To Buy SpringWorks Therapeutics Stock Online?
In order to purchase SpringWorks Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Tesla Stock: The Bear Case
The recent stock market drop has been a punishing time…
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
50
TREE alert for Mar 13
LendingTree [TREE] is up 1.53% over the past day.
Buy
57
INOD alert for Mar 13
Innodata [INOD] is down 7.4% over the past day.
Sell
40
VIST alert for Mar 13
Vista Energy SAB de CV [VIST] is up 0.36% over the past day.
